Personalized medicine tumor boards, which leverage genomic data to improve clinical management, are becoming standard for the treatment of many cancers. This paper is designed as a primer to assist clinicians treating head and neck squamous cell carcinoma (HNSCC) patients with an understanding of the discovery and functional impact of recurrent genetic lesions that are likely to influence the management of this disease in the near future. This manuscript integrates genetic data from publicly available aCGH and NGS genetics databases to identify the most common molecular alterations in HNSCC. The importance of these genetic discoveries is reviewed and how they may be incorporated into clinical care decisions is discussed. Considerations for the role of genetic stratification in the clinical management of head and neck cancer are maturing rapidly and can be improved by integrating data sets. This article is meant to summarize the discoveries made using multiple genomic platforms so that the head and neck cancer care provider can apply these discoveries to improve clinical care.
Acknowledgements from the authors
Grant Support: Dr. M. Giefing received funding from the Polish National Science Centre grant 2012/05/B/ NZ2/00870. Dr. M. Wierzbicka received funding from The National Centre for Research and Development grant INNOMED/I/7/NCBR/2014. Dr. J. Chad Brenner received funding from NIH Grants T32 DC005356 and U01DE025184. Dr. Ruud H. Brakenhoff from the Dutch Cancer Society/Alpe d’HuZes, the VUmc Cancer Centrum
Amsterdam foundation, and the European Commission.